← Browse by Condition
Medical Condition
urothelial carcinoma
Total Trials
13
Recruiting Now
13
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for urothelial carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — urothelial carcinoma Clinical Trials
How many clinical trials are currently recruiting for urothelial carcinoma?
ClinicalMetric currently tracks 13 actively recruiting clinical trials for urothelial carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 13. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for urothelial carcinoma?
urothelial carcinoma research spans Phase 1 (3 trials), Phase 2 (6 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a urothelial carcinoma clinical trial?
Eligibility criteria for urothelial carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 6
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT05646485
Recruiting
Enrollment
1,000 pts
Location
United States
Sponsor
University of Texas Southweste...
NCT07705035 Phase 1
Recruiting
Enrollment
210 pts
Location
United States
Sponsor
Duboce Biopharmaceuticals, Inc...
NCT07314723 Phase 2
Recruiting
Enrollment
90 pts
Location
China
Sponsor
Mabwell (Shanghai) Bioscience ...
NCT07234968
Recruiting
Enrollment
70 pts
Location
United States
Sponsor
Thomas Jefferson University
NCT06396533
Recruiting
Enrollment
92 pts
Location
United States
Sponsor
Fox Chase Cancer Center
NCT04510129
Recruiting
Enrollment
1,650 pts
Location
United States
Sponsor
Cofactor Genomics, Inc.
NCT07506057 Phase 2
Recruiting
Enrollment
20 pts
Location
China
Sponsor
Xiujuan Qu
NCT07421700 Phase 1, Phase 2
Recruiting
Enrollment
132 pts
Location
United States, Austr...
Sponsor
Pfizer
NCT06632262 Phase 2
Recruiting
Enrollment
202 pts
Location
China
Sponsor
Abbisko Therapeutics Co, Ltd
NCT07390617
Recruiting
Enrollment
50 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT07169734 Phase 1, Phase 2
Recruiting
Enrollment
180 pts
Location
United States, Franc...
Sponsor
Alentis Therapeutics AG
NCT04623502
Recruiting
Enrollment
600 pts
Location
United States
Sponsor
University of Texas Southweste...
NCT06695845 Phase 2
Recruiting
Enrollment
200 pts
Location
United States, South...
Sponsor
Jazz Pharmaceuticals
Related Conditions
colorectal cancer (3) bladder cancer (2) renal cell carcinoma (2) non small cell lung cancer (2) metastatic urothelial carcinoma (2) hematuria (1) smoking cessation (1) malignant germ cell tumor (1) lung adenocarcinoma (1) gastric esophageal gastroesophageal junction gej adenocarcinoma (1) endometrial adenocarcinoma (1) ovarian adenocarcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology